The protocol at a glance
There is no human dose or schedule in any source I found.
| Item | What the sources show |
|---|---|
| Human dose | Not established |
| Studied in | Cell cultures (human stem cells, skin cells, rat kidney cells) |
ClinicalTrials.gov lists no Cartalax trial (searched 5 Nov 2026). Wikipedia says only limited human studies exist but cites none.
Community notes report 2 mg under the skin daily for 10 to 20 days, 3 to 4 cycles a year. These are user reports, not trial data.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
No human results exist. Cell-culture findings:
Adv Gerontol 2014 (PMID 25946838); Bull Exp Biol Med 2016 (PMID 27259496).
Side effects
- No human safety data exists.
How it works
Gene activity in cells
In cell cultures, AED changed the activity of genes linked to ageing. Computer models suggest it can bind DNA, which is unproven in people.
Sources
- Tripeptides slow ageing in renal cell culture. Adv Gerontol 2014, PMID 25946838
- Peptide regulation of skin fibroblast functions during ageing in vitro. Bull Exp Biol Med 2016, PMID 27259496
- Cartalax (AED) identity: Wikipedia
- ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results